A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration
A Multicenter, Multiple-Dose Study in Neovascular Age-related Macular Degeneration (nAMD) to Evaluate the Safety, Tolerability, Pharmacodynamics, Immunogenicity, and Clinical Effect of Repeat Intravitreal (IVT) Injections of GEM103 as an Adjunct to Standard of Care Aflibercept Therapy
Sponsor: Gemini Therapeutics, Inc.
Terminated
Sponsor decision
Other terminated trials from Gemini Therapeutics, Inc.
More terminations from Gemini Therapeutics, Inc.
Other Macular Degeneration trials with similar outcome
Listed as NCT04684394, this PHASE2 trial focuses on Macular Degeneration and Neovascular Age-related Macular Degeneration and remains terminated or withdrawn. Sponsored by Gemini Therapeutics, Inc., it has been updated 9 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Apr 2022 — Nov 2022 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Dec 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gemini Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .